Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ProvexisCHIX:PXSL +3.00% Earnings per Share (Diluted) is £0.00 as of Sep. 2025. The stock has 1 warning sign investors should review. Among 787 Drug Manufacturers companies, Provexis ranks worse than 127064.68% on this metric.
Provexis's EPS (Basic) for the
six
months ended in Sep. 2025 was £0.00.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2025 was £0.00.
Provexis's EPS without NRI for the
six
months ended in Sep. 2025 was £0.00.
Its EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2025 was £0.00.
During the past 13 years, Provexis's highest 3-Year average EPS without NRI Growth Rate was 62.50% per year. The lowest was -14.50% per year. And the median was 25.65% per year.
Provexis (CHIX:PXSl) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Provexis Earnings per Share (Diluted) Related Terms
Provexis Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Provexis's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:PXSL vs ZTS, UTHR, VTRS: Earnings per Share (Diluted) Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Provexis's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Provexis PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Provexis's PE Ratio distribution charts can be found below:
* The bar in red indicates where Provexis's PE Ratio falls into.
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Provexis's Earnings Per Share (Diluted) for the fiscal year that ended in Mar. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of £0.00 mean?
Provexis (CHIX:PXSL) has a Earnings per Share (Diluted) of £0.00 as of Sep. 2025. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Provexis and its competitors. According to the industry distribution chart, Provexis ranks #999999 out of 787 companies in the Drug Manufacturers industry.
Is Provexis' Earnings per Share (Diluted) too high?
Provexis' current Earnings per Share (Diluted) is £0.00. Based on the distribution chart, Provexis ranks #999999 out of 787 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Provexis' Earnings per Share (Diluted) compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Provexis ranks #999999 out of 787 companies for Earnings per Share (Diluted). This places Provexis in the lower half of its industry. The industry median Earnings per Share (Diluted) is 9.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Drug Manufacturers company?
The median Earnings per Share (Diluted) among Drug Manufacturers companies is 9.90, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Provexis and its competitors. For the Drug Manufacturers industry, the median Earnings per Share (Diluted) is 9.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Provexis's current Earnings per Share (Diluted) is £0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Provexis stock overvalued right now?
Provexis (CHIX:PXSL) has a current Earnings per Share (Diluted) of £0.00. The current Earnings per Share (Diluted) is £0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Provexis (CHIX:PXSL), the current Earnings per Share (Diluted) is £0.00 as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Provexis PLC is engaged in developing, licensing and selling the proprietary, scientific Fruitflow heart-health functional food ingredient for the global functional food sector. The extract is available in two formats, a syrup and a powder, and it can be included in a broad range of food, beverage and dietary supplement formats.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:PXSL has been successfully added to your 
